CoChat

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

Godman, Brian, Shrank, William, Andersen, Morten, Berg, Christian, Bishop, Iain, Burkhardt, Thomas, Garuoliene, Kristina, Herholz, Harald, Joppi, Roberta, Kalaba, Marija, Laius, Ott, McGinn, Diane, Samaluk, Vita, Sermet, Catherine, Schwabe, Ulrich, Teixeira, Inês, Tilson, Lesley, Tulunay, F Cankat, Vlahović-Palčevski, Vera, Wendykowska, Kamila, Wettermark, Björn, Zara, Corinne, Gustafsson, Lars L · 2010 · Expert Review of Pharmacoeconomics & Outcomes Research
Cited by 153

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

AIM: The aim of this article was to evaluate the influence of different demand-side measures to enhance the prescribing of generics in ambulatory care based on cross-national comparisons. METHODS: An observational retrospective study was conducted using administrative databases from across Europe, documenting changes in reimbursed utilization and expenditure of different proton pump inhibitors (PPIs) and statins between 2001 and 2007, alongside different reforms to enhance prescribing efficiency. Utilization was converted to defined daily doses (DDDs) and expenditures were converted to euros. Demand-side measures were collated under the '4 Es'--education, engineering, economics and enforcement--to enable comparisons on the nature and intensity of reforms between countries. RESULTS: There were considerable differences in the utilization of generics and patent-protected PPIs and statins among Western European countries. Decreased utilization of omeprazole and simvastatin, alongside increased utilization of esomeprazole, atorvastatin and rosuvastatin, was seen in countries with limited demand-side measures to counteract commercial pressures. Prescribing restrictions, or a combination of education, prescribing targets and financial incentives, had the greatest influence on enhancing the utilization of omeprazole and simvastatin. For example, there was a threefold reduction in the utilization of atorvastatin in Austria following prescribing restrictions. Multiple demand-side interventions generally had a greater influence than single interventions, with the impact appearing additive. Multiple interventions coupled with initiatives to lower prices of generics considerably enhanced prescribing efficiency. CONCLUSION: This cross-national study has demonstrated considerable variation in the utilization and expenditure of PPIs and statins across Europe, providing opportunities to further improve prescribing efficiency. The '4 Es' do provide an understandable methodology to document and compare the influence of different demand-side measures, with the influence varying by their extent and intensity. Further reforms are essential given current financial pressures. Consequently, further research will concentrate on the potential to develop a scoring system to help predict the possible impact of different demand-side measures on future utilization patterns.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/erp.10.72

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., Garuoliene, K., Herholz, H., Joppi, R., Kalaba, M., Laius, O., McGinn, D., Samaluk, V., Sermet, C., Schwabe, U., Teixeira, I., Tilson, L., Tulunay, F. C., Vlahović-Palčevski, V., Wendykowska, K., Wettermark, B., Zara, C., & Gustafsson, L. L.
Venue
Expert Review of Pharmacoeconomics & Outcomes Research
Published
2010-12
Volume
10
Issue
6
Pages
707-722
ISSN
  • 1473-7167 (ISSN-L)
  • 1744-8379
OpenAlex
W2160675720
Cited by
153
References
7
FWCI
39.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.